Filing Flows › BioMarin Pharmaceutical (BMRN) › Guidance & outlook

BioMarin Pharmaceutical (BMRN) guidance and outlook

BioMarin Pharmaceutical's 10-Q filed Nov 3, 2026 makes 16 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 3, 2026

• (1) In 2026, we announced that we will no longer market ROCTAVIAN.
• Under the terms of the agreement, we will make an upfront payment of $70.0 million that will be recorded as acquired IPR&D expense in the fourth quarter of 2026.
• The acquisition is intended to strengthen our Skeletal Conditions pipeline by adding BMN 440 (formerly ALE1), an orally active, small molecule for the potential treatment of hypophosphatasia (HPP).
• • In July 2026, we announced that the FDA accepted our sNDA for full approval of VOXZOGO in children with achondroplasia, with a PDUFA target action date of February 28, 2027.
• We expect that the timing of these large government orders will continue to be inconsistent, which has created in the past and may continue to create significant period to period variation in our revenues.
• We manage our R&D expense by identifying the R&D activities we anticipate will be performed during a given period and then prioritizing efforts based on scientific data, probability of successful development, market potential, available human and capital resources and other similar considerations.
• We continually review our product pipeline and the development status of product candidates and, as necessary, reallocate resources among the research and development portfolio that we believe will best support the future growth of our business.
• We expect acquired IPR&D to increase in the fourth quarter of 2026 related to the upfront payment for BMN 450.
• With the addition of the acquired intangible assets, we expect amortization of intangible assets to increase over the next 12 months.
• We expect Interest income to decrease over the next 12 months due to lower cash and investment balances.
• We expect Interest expense to increase over the next 12 months due to long-term debt financings completed in 2026.
• We believe we will meet longer-term expected future cash requirements and obligations through a combination of cash flows from operating activities and available cash.

BioMarin Pharmaceutical's latest quarter

Questions

What does BioMarin Pharmaceutical expect?

(1) In 2026, we announced that we will no longer market ROCTAVIAN. Under the terms of the agreement, we will make an upfront payment of $70.0 million that will be recorded as acquired IPR&D expense in the fourth quarter of 2026. The acquisition is intended to strengthen our Skeletal Conditions pipeline by adding BMN 440 (formerly ALE1), an orally active, small molecule for the potential treatment of hypophosphatasia (HPP).

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.